drugset / Trial / NCT05054374
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study to find out whether mirdametinib is a safe treatment for people with advanced solid tumor cancer that has certain mutations. Researchers will look at whether mirdametinib on its own or in combination with the drug fulvestrant is a safe treatment that causes few or mild side effects in people with advanced solid tumor cancer.
Timeline
- Start
- 2021-09-14
- Primary completion
- 2023-10-26
- Completion
- 2023-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirdametinib | Small molecule | 2 mg | Oral |
| Subject | Mirdametinib | Small molecule | 3 mg | Oral |
| Subject | Mirdametinib | Small molecule | 4 mg | Oral |
| Subject | Mirdametinib | Small molecule | 6 mg | Oral |
| Subject | Mirdametinib | Small molecule | 8 mg | Oral |
| Background | Fulvestrant | Small molecule | — | — |